Trial Profile
A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Abiraterone; Enzalutamide; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 06 Apr 2021 Primary endpoint (Clinical benefit rate) has been met as per the results published in the Annals of Oncology.
- 06 Apr 2021 Status changed from active, no longer recruiting to completed as per the results published in the Annals of Oncology.
- 06 Apr 2021 Results evaluating whether there is a preferred treatment sequence option and reporting final study results, published in the Annals of Oncology.